Local No. 8 IBEW Retirement Plan v. Vertex Pharmaceuticals Inc., 140 F. Supp. 3d 120

Background

Vertex announced May 7, 2012 interim Phase II results reporting ‘‘absolute’’ lung-function improvements for a VX-809 + Kalydeco combination; the press release was later corrected (May 29) to state the results were ‘‘relative.’'
The May 7 announcement caused a large, immediate stock spike (from ≈$37 to ≈$58 close) and very high volume; stock later corrected but remained above pre‑announcement levels.
Several Vertex executives (notably Nancy Wysenski) sold significant amounts of stock in the days after May 7; plaintiffs allege sales were unusually large and suspiciously timed.
Confidential witnesses alleged the company had the data up to two weeks before the release and some employees were skeptical (e.g., lack of sweat chloride improvement), suggesting defendants ‘‘turned a blind eye.’'
Local No. 8 IBEW Retirement Plan bought Vertex shares after May 7 but before the May 29 correction and sued under §10(b)/Rule 10b‑5, §20(a), and §20A; defendants moved to dismiss for failure to plead scienter with particularity.
The court granted the motion to dismiss: it found the complaint alleged negligence at most and that insider sales plus the other allegations did not create the required "strong inference" of scienter; §20(a) and §20A claims were dismissed as derivative.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Whether complaint pleads a "strong inference" of scienter for the May 7 misstatement	The May 7 results were "too good to be true," defendants had access to data before release and recklessly failed to verify, supporting conscious disregard	Press release error was a mistake or negligence; no specific factual allegations that any defendant knew the statement was false	Dismissed — allegations show negligence at best; no cogent, compelling inference of scienter
Whether insider sales create or materially augment scienter inference	Large, clustered insider sales (539,000+ shares, ~$31.9M) immediately after announcement support inference defendants traded on known falsity	Sales have innocent explanations (retirement, option exercise, 10b5‑1 plans, routine sales, small % of holdings)	Insider sales insufficient alone or in combination to create a strong inference of scienter
Sufficiency of confidential witness allegations to plead recklessness	CWs say data existed earlier, some employees were skeptical, and internal review occurred — implying defendants ignored obvious problems	CW allegations are general, lack detail tying specific defendants to raw data or showing they could have or would have detected the error	CW statements do not supply particularized facts showing defendants had actual knowledge or high degree of reckless disregard
Viability of §20(a) and §20A claims	§20(a)/§20A alleged based on underlying Rule 10b‑5 violation and contemporaneous insider trading	Defendants argue those claims fail if the §10(b) claim fails	Dismissed — both claims derivative of the dismissed Rule 10b‑5 claim

Key Cases Cited

Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007) (defines "strong inference" of scienter and comparative evaluation standard)
ACA Fin. Guar. Corp. v. Advest, Inc., 512 F.3d 46 (1st Cir. 2008) (courts must evaluate scienter holistically and weigh competing inferences)
Mississippi Pub. Employees’ Ret. Sys. v. Boston Scientific Corp., 649 F.3d 5 (1st Cir. 2011) (scienter requires intent or extreme recklessness; insider trading cannot establish scienter alone)
New Jersey Carpenters Pension & Annuity Funds v. Biogen IDEC Inc., 537 F.3d 35 (1st Cir. 2008) (confidential witness standards; insider trading as corroborating evidence)
Greebel v. FTP Software, Inc., 194 F.3d 185 (1st Cir. 1999) (insider trading and scienter context; caution that unusual sales alone are insufficient)
In re VeriFone Holdings, Inc., 704 F.3d 694 (9th Cir. 2012) (contrast case where repeated, suspicious accounting adjustments supported a strong inference of deliberate recklessness)
Ernst & Ernst v. Hochfelder, 425 U.S. 185 (1976) (scienter defined as intent to deceive, manipulate, or defraud)
SEC v. Fife, 311 F.3d 1 (1st Cir. 2002) (recklessness standard defined for securities fraud)
In re Boston Scientific Corp. Sec. Litig., 686 F.3d 21 (1st Cir. 2012) (internal records/admissions and warnings are strong evidence of scienter)
City of Dearborn Heights Act 345 Police & Fire Ret. Sys. v. Waters Corp., 632 F.3d 751 (1st Cir. 2011) (elements of §10(b) claim and §20(a) derivative nature)